Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



Key Enabling Technologies (KETs) Observatory initiative of the European Commission.

The KETs Observatory is an online monitoring platform that aims to provide the EU, national and regional policy makers and business stakeholders with quantitative and qualitative information on the deployment of Key Enabling Technologies (KETs) both within the EU and in comparison with other world regions (e.g. East Asia, North America). As contract holders of the second phase of this initiative, PricewaterhouseCoopers (PwC) are currently working on on patents, production, employment and trade for each key enabling technology. The data are available in a database format, as well as in the individual country prupdating and advancing the KETs Observatory website. PwC are publishing the most recent sets of quantitative data ofiles for EU and non-EU countries. Additionally, they have published a series of analytical reports on specific promising KETs-based products, that have a high potential for large-scale manufacturing in Europe. No comparable initiative exists on this scale. This type of informatio ...

Read the rest of entry »

Evox raises €37m in Series B Round

Oxford, UK: Exosome drug delivery specialist Evox Therapeutics Ltd has closed a €37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) and Cowen Healthcare Investments.

Read the rest of entry »

Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases

Philadelphia, PA, USA: Ossianix, Inc. today announced a research collaboration and option agreement with Novo Nordisk to deliver therapeutic molecules in diabetes and other metabolic diseases across the Blood Brain Barrier (BBB) to the brain.

Read the rest of entry »

Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines

BOSTON & OXFORD, UK:  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines,

Read the rest of entry »

Oxford Genetics secures a multi-million pound contract

Oxford Genetics has secured a multi-million pound contract with a global ecommerce provider of reagents and tools to the research and clinical community.

Oxford Genetics is a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery with operations in the UK and US. It has significant expertise in DNA design, virus and protein-based biologics and cell lines, and is working with leading research, diagnostic and therapeutic companies and research institutes. The company’s extensive use of hardware and software automation allows it to develop new and innovative solutions, the latest of which is its mammalian CRISPR cell line engineering platform.

Read the rest of entry »

Engineering immune cells to treat cancers

AMSBIO produce a growing range of experimental cell lines, recombinant proteins and screening services to advance the search for new Chimeric Antigen Receptor (CAR T) cell therapies to treat cancers.

For years, the foundations of cancer treatment were surgery, chemotherapy, and radiation therapy. Over the last twenty years, therapeutic drugs that target cancer cells by homing in on specific molecular changes seen primarily in those cells, have also become standard treatments for many cancers. In the last few years - immunotherapies that enlist and strengthen the power of a patient’s immune system to attack tumors have emerged as a new and very promising cancer treatment.

Read the rest of entry »

UK Government consultation to allow NICE to charge companies for making reimbursement submissions. Why especially small companies should respond.

The National Institute for Health and Care Excellence (NICE) provides reimbursement guidance to the National Health Service (NHS) in England and Wales. The NHS is legally obliged to provide funding for medicines and treatments recommended by NICE’s health technology appraisal (HTA) programmes.

Read the rest of entry »

Mologic commences clinical trial of urine-based diagnostic for cystic fibrosis

Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, has recently announced that it has commenced a clinical trial to evaluate the Company’s urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis (CF) patients. The study aims to identify five urinary biomarkers associated with the onset of pulmonary exacerbation in adults with CF. It will also validate the use of the novel point-of-care (POC) test for patient’s self-monitoring of their condition.

Read the rest of entry »

AMSBIO have designed The TUNR Flexible Gene Editing System

AMSBIO TUNR kits allows you to precisely tune gene expression from 100% all the way down to complete knockout, model ranges of gene expression reflecting diversity in patient populations and knockdown essential genes where knockout would result in lethality. In addition, a kit is available that allows you to control endogenous gene expression enabling elimination of artifacts from ectopic expression. The TUNR Flexible Gene Editing System for Endogenous Genes is designed to generate four cell lines or animal models with four different levels of knockdown of your endogenous gene of interest. The TUNR Targeted Transgenic kit enables you to insert your gene of interest under TUNR control into the AAVS1 locus. AAVS1 is a safe place to integrate transgenes, allowing predictable expression from a locus known not to alter the expression of other genes or have otherwise negative effects on the cell. The TUNR Plasmid-Delivered Transgenes kit allows you to control the expression of a transgene. Using the kit, y ...

Read the rest of entry »

Breakpoint mapping of a novel de novo translocation t(X;20)(q11.1;p13) by positional cloning and long read sequencing

Disease associated chromosomal rearrangements often have break points located within disease causing genes or in their vicinity. The purpose of this study is to characterize a balanced reciprocal translocation in a girl with intellectual disability and seizures by positional cloning and whole genome sequencing. The translocation was identification by G- banding and confirmed by WCP FISH. Fine mapping using BAC clones and whole genome sequencing using Oxford nanopore long read sequencing technology for a 1.46 X coverage of the genome was done. The positional cloning showed split signals with BAC RP11-943 J20. Long read sequencing analysis of chimeric reads carrying parts of chromosomes X and 20 helped to identify the breakpoints to be in intron 2 of ARHGEF9 gene on Xp11.1 and on 20p13 between RASSF2 and SLC23A2 genes. This is the first report of translocation which successfully ...

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.